Mark Coleman

Director Mark Coleman sold 17,537 shares over 3 days (May 29–Jun 2) for $4,019,470.43 via scheduled 10b5-1 plan at AXSM

Mark Coleman, a Director at Axsome Therapeutics, executed 3 separate sales totaling 17,537 shares for $4,019,470.43 between May 29 and June 2, 2026, reducing his holdings by 37.2% to 29,603 shares post-transaction. This disposition was effected through a pre-arranged 10b5-1 trading plan—a scheduled, non-discretionary mechanism—so the timing and execution reflect contractual commitment rather than a discretionary market timing decision. The company remains unprofitable with a full-year net income of $-64,542,000.00, though it is growing revenue at an annual rate of +65.6%. Across his prior 3 sales at this ticker, Coleman's average 90-day return was +45.6%, indicating that his prior open-market dispositions at AXSM were followed by stock appreciation; however, the current stock price of $245.64 is only 1.3% above its 52-week high of $242.41, and this scheduled 10b5-1 execution carries no forward-looking signal independent of the plan's predetermined terms.

Director Coleman Mark sold 25,000 AXSM shares at $161.11 (2026-02-26) via 10b5-1 plan; retains 47,140 shares

Coleman Mark, a director of Axsome Therapeutics, sold 25,000 shares at $161.11 per share for a total value of $4,027,750.00 under a pre-arranged 10b5-1 trading plan, reducing his holdings by 34.7% from 72,140 to 47,140 shares. The scheduled nature of the transaction means this sale was not made on a discretionary basis, limiting inferences about current sentiment toward the company. The director's continued retention of 47,140 shares indicates an ongoing equity stake in the business, though the magnitude of the reduction should be noted in the context of his overall holdings profile.

Director Coleman Mark purchased 1,575 shares at blended $127.28 (3 transactions 2025-09-08)

Coleman Mark, a director at Axsome Therapeutics, executed 3 separate purchases on 2025-09-08 totaling 1,575 shares for $200,466.30, increasing his holdings from 46,637 to 48,212 shares (+3.4%). The purchases occurred at prices ranging from $127.20 to $127.40 against a current price of $125.68—a location near the middle of the 52-week range ($80.05–$137.75). Over the past month, AXSM stock has appreciated +19.9%, and the company demonstrates strong fundamentals with annual revenue growth of +42.5% on $150.0M in latest quarterly revenue, though the firm remains unprofitable with $-48.0M net income. Notably, Mark's prior two transactions at this ticker (both sells in 2023-09-15) exhibited a 100% well-timed rate at the 90-day mark, suggesting his historical patterns at AXSM have been favorable; however, the present transaction is a buy executed after recent price strength, not preceded by the depressed pricing that characterized his prior dispositions.